Building the Next Immunology Leader
Corporate Presentation - July 2023
Forward-Looking Statements Disclaimer
This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believe," "predict," "potential," "continue," "strategy," "future," "opportunity," "would," "seem," "seek," "outlook" and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. You should carefully consider the risks and uncertainties described in the "Risk Factors" sections of Zura Bio's recent filings with the SEC. These filings would identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Many of these factors are outside Zura Bio's control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this communication, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against Zura Bio;
- volatility in the price of Zura Bio's securities; (3) the ability of Zura Bio to successfully conduct research and development activities, grow and manage growth profitably, maintain relationships with customers and suppliers, and retain key employees; (4) costs related to financing transactions and the ongoing costs relating to operating as a public company; (5) changes in the applicable laws or regulations; (6) the possibility that Zura Bio may be adversely affected by other economic, business, and/or competitive factors; (7) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Zura Bio operates; (8) the impact of the global COVID-19 pandemic; (9) the potential inability of Zura Bio to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (10) the enforceability of Zura Bio's intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (11) other risks and uncertainties described in the Registration Statement and such other documents filed by Zura Bio from time to time with the SEC. These risks and uncertainties may be amplified by the COVID-19 pandemic or other unanticipated global disruption events, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations.
Zura Bio does not undertake or accept any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.
©2023 Zura Bio Ltd. | 2 |
Experienced management team with proven ability to
successfully execute and build a leading market position
Multiple Phase 2 ready assets in important, underserved
indications including SSc, HS and Asthma
Public on Nasdaq in March 2023
Well capitalized with > $100M cash,* including $80M PIPE
in June (Deep Track Capital, Great Point Partners, Suvretta Capital, others) to support development and operations through 2026, including key data readouts
(*) As of July 2023 | © 2023©2023Zura ZuraBio LtdBio. Ltd. | 3 |
ABBREVIATIONS: HS, Hidradenitis suppurativa; SSc, Systemic sclerosis |
Experienced management team with proven ability to successfully execute and build a leading market position
Someit Sidhu M.D. | Verender Badial | Chris Cabell M.D. | ||||
Chief Executive Officer and Director | Chief Financial Officer | Chief Medical Officer and | ||||
Head of Research and Development |
Mike Howell Ph.D. | ||||||
Gary Whale Ph.D. | Kim Davis | |||||
Chief Technology Officer | Chief Legal Officer | Chief Scientific Officer and | ||||
Head of Translational Science | ||||||
BOARD OF DIRECTORS
Amit Munshi
Chairman
Garry Neil, M.D.
Director
Jennifer Jarrett
Director
Neil Graham, M.D.
Director
Parvinder Thiara
Director
Sandeep Kulkarni, M.D.
Director
Steve Schoch
Director
©2023 Zura Bio Ltd. | 4 |
Sizeable Total Addressable Market Exists Across
Number of Validated Mechanisms
Large TAM present a ~$20B opportunity
Projected TAMs (revenue forecasts for commercial products)(1)
$20B
Mechanisms validated across an array of indications
IL-17 | TSLP | BAFF | IL-33 |
IL-33 | |
$15B | BAFF |
TSLP | |
$10B |
Mkt.
Filed
Ph3
Psoriasis, Psoriatic arthritis, Ankylosing spondylitis
Hidradenitis
suppurativa, Axial
spondylarthritis
Uveitis
Asthma | SLE, | - |
Lupus nephritis | ||
- | - | - |
Nasal polyps, | Sjögren's syndrome, | COPD, |
Eosinophilic | ||
IgAN | Asthma | |
esophagitis | ||
$5B
$0
IL-17
Ph2
-
Autoimmune | Atopic dermatitis, | |
COPD, | hepatitis, Systemic | |
Diabetic kidney | ||
CSU | sclerosis, NMO | |
disease | ||
spectrum disorder | ||
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Sources: Evaluate Pharma. FactSet. Data as of 07/21/23. | ©2023 Zura Bio Ltd. | 5 |
(1) Assets included in projected TAM: Cosentyx, Taltz, Bimzelx and Siliq (IL-17), Tezspire (TSLP), Benlysta (BAFF) and itepekimab and tozorakimab (IL-33). |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Zura Bio Ltd. published this content on 31 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 July 2023 15:18:05 UTC.